Sanofi (SNY) Income towards Parent Company (2009 - 2026)
Sanofi (SNY) posted Income towards Parent Company of -$7.6 billion for Q2 2026, down 502.12% sequentially from $1.9 billion in Q1 2026, and down 270.37% YoY from $4.5 billion in Q2 2025.
Sanofi (SNY) Income towards Parent Company (2009 - 2026) Analysis & Trends
Sanofi has reported Income towards Parent Company for 18 years, with the latest figure at -$7.6 billion in Q2 2026.
- Quarterly Income towards Parent Company fell 270.37% year-over-year to -$7.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$3.3 billion (down 133.19% YoY) and the FY2025 annual result came in at $9.1 billion, up 53.07% from the prior year.
- Income towards Parent Company slipped to -$7.6 billion in Q2 2026 per SNY's latest filing, from $1.9 billion in the prior quarter.
- Over five years, Income towards Parent Company peaked at $10.1 billion in Q3 2025 and troughed at -$7.7 billion in Q4 2025.
- A 5-year average of $1.4 billion and a median of $1.9 billion in 2025 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 272.1% in 2025, down 1543.62% in 2025.
- Over 5 years, Income towards Parent Company stood at $5.4 billion in 2022, then sank by 111.13% to -$597.1 million in 2023, then jumped by 189.3% to $533.2 million in 2024, then sank by 1543.62% to -$7.7 billion in 2025, then rose by 1.29% to -$7.6 billion in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$7.6 billion, $1.9 billion, and -$7.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Bn |
| Mar 31, 2026 | 1.89 Bn |
| Dec 31, 2025 | -7.70 Bn |
| Sep 30, 2025 | 10.07 Bn |
| Jun 30, 2025 | 4.46 Bn |
| Mar 31, 2025 | 1.97 Bn |
| Dec 31, 2024 | 533.23 Mn |
| Sep 30, 2024 | 3.09 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 1.23 Bn |
| Dec 31, 2023 | -597.15 Mn |
| Sep 30, 2023 | 2.75 Bn |
| Jun 30, 2023 | 1.56 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 5.37 Bn |
| Sep 30, 2022 | 2.09 Bn |
| Jun 30, 2022 | 1.25 Bn |
| Mar 31, 2022 | 2.25 Bn |
| Dec 31, 2021 | 5.80 Bn |
| Sep 30, 2021 | 2.72 Bn |